The name polycystic ovary syndrome may have unintentionally narrowed how medicine understood one of the most common endocrine disorders affecting women. The ovaries were visible. The deeper physiology was not.
For decades, the syndrome was largely framed around irregular ovulation, infertility, excess androgen symptoms, and the characteristic “string of pearls” appearance seen on ultrasound. Yet many patients experienced something far broader long before medicine fully acknowledged it. They struggled not only with irregular cycles, but also with weight changes, insulin resistance, fatigue, inflammation, mood disturbances, acne, and metabolic dysfunction that often seemed disconnected from the reproductive label attached to the condition.
Even the name itself carried misconceptions. The “cysts” in polycystic ovary syndrome are not true cysts at all, but rather small arrested follicles that fail to mature and ovulate normally. Some women diagnosed with the syndrome may not demonstrate classic polycystic ovarian morphology on ultrasound, while others with polycystic-appearing ovaries may not meet diagnostic criteria for the syndrome itself. Increasingly, clinicians and researchers have begun to recognize that the ovarian findings, while clinically important, may represent only one visible manifestation of a much larger systemic process.
This growing recognition has contributed to an international movement to reconsider the terminology surrounding the condition. In 2026, an international consortium of experts proposed the term polyendocrine metabolic ovarian syndrome (PMOS), reflecting a broader understanding that the syndrome extends beyond ovarian morphology alone. The proposed terminology emphasizes the interplay between endocrine regulation, metabolism, and ovarian function rather than focusing narrowly on the appearance of the ovaries themselves.
The shift is more than semantic. Names shape how diseases are conceptualized, researched, diagnosed, and treated. They also shape how patients understand themselves.
For years, many patients with PCOS moved through fragmented systems of care. A dermatologist addressed acne. A gynecologist addressed irregular bleeding. A fertility specialist addressed anovulation. A primary care physician addressed prediabetes or obesity. Yet the underlying physiology connecting these manifestations was often discussed in isolated compartments rather than as part of an interconnected network.
The ovary was not incorrectly implicated. But it may have been disproportionately blamed.
Reproductive dysfunction in PCOS is undeniably real. The syndrome remains one of the leading causes of anovulatory infertility worldwide. Elevated androgen levels disrupt follicular development, ovulation becomes irregular or absent, and many patients experience profound emotional distress surrounding fertility and reproductive timing. However, mounting evidence suggests the ovary may function less like an isolated malfunctioning organ and more like an end-organ responding to signals arising from multiple physiologic systems simultaneously.
Insulin resistance appears to play a central role in many patients, though not all phenotypes demonstrate identical metabolic patterns. Neuroendocrine dysregulation involving gonadotropin-releasing hormone (GnRH) pulsatility and luteinizing hormone (LH) secretion may contribute to persistent androgen excess and follicular arrest. Adipose tissue itself functions as an active endocrine organ, contributing inflammatory cytokines and metabolic signaling that may further amplify dysfunction. Hepatic metabolism influences sex hormone-binding globulin production, altering circulating androgen activity. Emerging evidence also suggests anti-Mullerian hormone (AMH), long viewed primarily as a marker of ovarian reserve, may participate more actively in the neuroendocrine feedback loops underlying the syndrome.
What is increasingly apparent is that the condition cannot be fully explained by the ovary alone.
At the same time, it is important not to oversimplify the biology in the opposite direction. PCOS is highly heterogeneous, and researchers continue to debate the relative contribution of metabolic, neuroendocrine, adrenal, inflammatory, genetic, and environmental drivers across different phenotypes of the syndrome. Some patients demonstrate profound insulin resistance. Others are lean and metabolically less overtly affected. Some primarily exhibit hyperandrogenic symptoms, while others present with ovulatory dysfunction as the dominant feature. It is entirely possible that what we currently classify under a single diagnostic umbrella may ultimately represent several overlapping but biologically distinct syndromes.
Still, the systems-based view helps explain why many patients often sensed something broader was happening long before clinicians articulated it scientifically. Many women with PCOS have described feeling dismissed when symptoms were reduced solely to weight or fertility. Some were told simply to “lose weight” without acknowledgment of the metabolic and hormonal forces complicating weight regulation itself. Others spent years moving between specialists without anyone explaining how their symptoms connected to one another. Many recognized intuitively that the syndrome affected energy, mood, metabolism, appetite, skin, and overall health in ways that extended far beyond reproduction alone.
The emerging PMOS framework does not diminish the importance of the ovary. Rather, it places ovarian dysfunction within a wider physiologic context. The ovary remains central to the clinical manifestations of the syndrome, but increasingly appears to function within an interconnected network involving the hypothalamus, liver, adipose tissue, pancreas, and broader endocrine signaling pathways.
This evolving understanding also carries important implications for the future of reproductive medicine. Increasingly, the challenge is no longer simply treating ovaries, but understanding the dynamic systems surrounding them. Newer research is exploring how insulin signaling pathways, hypothalamic regulation, inflammatory networks, AMH amplification, and metabolic therapies may interact in ways previously underappreciated. Future treatments may become increasingly phenotype-specific, targeting the dominant physiologic drivers present in each individual patient rather than applying a single framework to all.
Perhaps the most important lesson is not that the ovary was wrongfully blamed, but that medicine is finally beginning to see the syndrome the way many patients have experienced it all along: systemic, interconnected, and deeply personal.
Oluyemisi (Yemi) Famuyiwa is a renowned fertility specialist and founder, Montgomery Fertility Center, committed to guiding individuals and couples on their path to parenthood with personalized care. With a background in obstetrics and gynecology from Georgetown University Hospital and reproductive endocrinology and infertility from the National Institutes of Health, she offers cutting-edge treatments like IVF and genetic testing. She can be reached on Linktr.ee, LinkedIn, YouTube, Facebook, Instagram @montgomeryfertility, and X @MontgomeryF_C.
Dr. Famuyiwa is dedicated to advancing fertility care through research, publications, and educational efforts, including hosting the Fertile Talks podcast. Beyond her clinic, she advocates holistic health and enjoys nature walks. Recognized for her excellence, she is a Castle Connolly Top Doctor and a Women Who Move Maryland honoree. Dr. Famuyiwa’s participation in the Zenith Total Health Expo 2024 reflects her commitment to empowering individuals with knowledge about nutrition, lifestyle, and fertility.
She is the author of “IGF-I and Uterine Growth,” a chapter in the Excerpta Medical International Congress Series, 1997. This work delves into the significant role of Insulin-like Growth Factor I (IGF-I) in uterine development. She also authored “Sex Steroid Regulation of IGF System Gene Expression and Proliferation in Primate Myometrium,” published in the Journal of Clinical Endocrinology and Metabolism in 1996, which explores the regulation of IGF system gene expression by sex steroids and its impact on cellular proliferation in the primate myometrium.
